Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jul 31;10(1):12923.
doi: 10.1038/s41598-020-69762-w.

Vitamin D supplementation effects on the clinical outcomes of patients with coronary artery disease: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Vitamin D supplementation effects on the clinical outcomes of patients with coronary artery disease: a systematic review and meta-analysis

Leila Sadat Bahrami et al. Sci Rep. .

Abstract

In this systematic review and meta-analysis our aim was to assess the effect of vitamin D supplementation on cardiac outcomes in patients with coronary artery disease (CAD). The search terms were performed from January 2000 to January 2018, only randomized clinical trials (RCT) in human subjects were considered, with no language restrictions. The electronic databases used in this study were: PubMed; Cochran library; Embase; and Scopus. Two independent expert reviewers carried out data extraction according to Cochrane recommendations. Only four RCTs were found in relation to the effects of vitamin D supplementation on the coronary artery disease. In these 299 patients, vitamin D supplementation had significant favorable effects on Diastolic Blood Pressure (DBP) (- 2.96, p = 0.02) and Parathyroid hormone (PTH) (- 4.05, p < 0.001). However, it had no significant effects on hs-CRP mean difference (- 0.04, p = 0.25), total cholesterol (TC) (- 0.46, p = 0.83), triglyceride (TG) (0.68, p = 0.89), low-density lipoproteins (LDL) (2.08, p = 0.56), and high-density lipoproteins (HDL) (- 2.59, p = 0.16). In conclusion, the use of vitamin D was associated with improvements in some cardiac outcomes of CAD patients with vitamin D deficiency. Also, further research is needed to clarify these results.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
PRISMA flow-diagram of the study selection process.
Figure 2
Figure 2
Forest plot of randomized controlled trials showing weighted mean difference in hs-CRP concentrations between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the non-significant effect of vitamin D supplement on reducing hs-CRP concentrations was observed (P value for heterogeneity = 0.75, and χ2 = 0.58).
Figure 3
Figure 3
Forest plot of randomized controlled trials showing weighted mean difference in total Cholesterol levels between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the non-significant effect of vitamin D supplement on reducing total Cholesterol levels was observed (P value for heterogeneity = 0.89, and χ2 = 0.23).
Figure 4
Figure 4
Forest plot of randomized controlled trials showing weighted mean difference in triglyceride levels between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the non-significant effect of vitamin D supplement on reducing triglyceride levels was observed (P value for heterogeneity = 0.68, and χ2 = 0.78).
Figure 5
Figure 5
Forest plot of randomized controlled trials showing weighted mean difference in LDL levels between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the non-significant effect of vitamin D supplement on reducing LDL levels was observed (P value for heterogeneity = 0.77, and χ2= 0.52).
Figure 6
Figure 6
Forest plot of randomized controlled trials showing weighted mean difference in HDL levels between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the non-significant effect of vitamin D supplement on HDL levels was observed (P value for heterogeneity = 0.22, and χ2 = 1.51).
Figure 7
Figure 7
Forest plot of randomized controlled trials showing weighted mean difference in SBP levels between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the non-significant effect of vitamin D supplement on systolic blood pressure levels was observed (P value for heterogeneity = 0.11, and χ2 = 2.50).
Figure 8
Figure 8
Forest plot of randomized controlled trials showing weighted mean difference in DBP levels between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the significant effect of vitamin D supplement on reducing diastolic blood pressure levels was observed (P value for heterogeneity = 0.69, and χ2 = 0.16).
Figure 9
Figure 9
Forest plot of randomized controlled trials showing weighted mean difference in PTH concentrations between the vitamin D-supplemented and placebo groups for all eligible studies. For all the inclusion studies pooled, the significant effect of vitamin D supplement on reducing PTH concentrations was observed (P value for heterogeneity = 0.42, and χ2 = 0.66).

References

    1. Mozaffarian D, et al. Executive summary: Heart disease and stroke statistics—2016 update: A report from the American Heart Association. J. Circ. 2016;133:447–454. doi: 10.1161/CIR.0000000000000366. - DOI - PubMed
    1. Thiene G, Corrado D, Basso C. Sudden Cardiac Death in the Young and Athletes: Text Atlas of Pathology and Clinical Correlates. New York: Springer; 2016.
    1. Bcheraoui C, et al. Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: Findings from the Global Burden of Disease 2015 study. J. Int. J. Public Health. 2018;63:137–149. - PMC - PubMed
    1. Libby P, Theroux P. Pathophysiology of coronary artery disease. J. Circ. 2005;111:3481–3488. doi: 10.1161/CIRCULATIONAHA.105.537878. - DOI - PubMed
    1. Chakravarty S. Pathogenesis of atherosclerosis. Handb Lipidol. 2016;28:28–31. doi: 10.5005/jp/books/12757_5. - DOI

MeSH terms